News

Hypha’s paper in ACS Medicinal Chemistry Letters on “Biotransformation: Impact and Application of Metabolism in Drug Discovery” was published in August 2020.

Check out a new white paper describing the joint efforts of Hypha and Galchimia, who together successfully synthesised metabolites of the herbicide napropamide using a complementary approach of chemical synthesis and microbial biotransformation. The joint project was successful in providing a comprehensive family of compounds relevant for the risk assessment of napropamide.

Hypha were honoured to be asked to contribute a chapter on “Metabolite Generation and Metabolite Characterization by NMR” in the book just published on “Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters”, edited by Shuguang Ma and Swapan Chowdhury.

Hypha are excited to announce they have relocated from Slough to Milton Park in Oxfordshire, one of the largest science clusters in the UK.

Metabolites derived from any human flavin-containing monooxygenase (FMO) subtype can now be produced as a service offering at Hypha. Recombinant enzymes of all five forms of human FMOs have been cloned into E.coli to provide a mechanism to access scalable quantities of FMO derived metabolites.

Great to see Hypha recognised for producing a glucuronide metabolite of praliciguat (M3) in the paper just out in the journal Pharmacology Research & Perspectives.

Hypha remain fully operational and are monitoring the COVID-19 situation closely. We have implemented a number of measures in response to the guidelines issued by the UK Government to ensure that our clients’ projects proceed as planned, while preserving the health and safety of our staff and the wider community.